### In the claims:

1. (Currently Amended) A compound of Formula I

$$R^1$$
 $R^3$ 
 $O-R^2$ 

wherein

R<sup>1</sup> is selected from

hydrogen,
halogen,
substituted or unsubstituted C1-C10 alkyl,
substituted or unsubstituted C2-C10 alkenyl,
substituted or unsubstituted C2-C10 alkynyl,
substituted or unsubstituted aryl,
substituted or unsubstituted C3-C10 cycloalkyl,
-(CRa2)nOR4, and
-(CRa2)tC(O)OR4;

said alkyl, alkenyl, alkynyl, aryl, and cycloalkyl, is optionally substituted with one or more of R7;

## R<sup>2</sup> is selected from

hydrogen, substituted or unsubstituted aralkyl, substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> alkyl, substituted or unsubstituted aryl, and substituted or unsubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl;

R<sup>3</sup> is selected from

halogen,
–C(O)R<sup>4</sup>,

substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> alkyl, substituted or unsubstituted aryl, substituted or unsubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl, substituted or unsubstituted C<sub>2</sub>-C<sub>10</sub> alkenyl, and substituted or unsubstituted C<sub>2</sub>-C<sub>10</sub> alkynyl;

## R4 is independently selected from

0

hydrogen, substituted or unsubstituted C1-C10 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C2-C10 alkenyl, and substituted or unsubstituted C2-C10 alkynyl;

# R6 is independently selected from

substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, and halogen;

# R<sup>7</sup> is independently selected from

 $-(CRa_2)_nOR^4$ ,

hydrogen,
halogen,
substituted or unsubstituted C1-C10 alkyl,
substituted or unsubstituted C2-C10 alkenyl,
substituted or unsubstituted C2-C10 alkynyl,
substituted or unsubstituted C3-C10 cycloalkyl,
substituted or unsubstituted aryl,
-NO2,
-NR4(CRa2)nC(O)R4,
-(CRa2)nNR42,
-(CRa2)nNR4(CRa2)nR6,
-CN,
-(CRa2)nC(O)R4,
-(CRa2)nC(O)CRA,
-(CRa2)nC(O)CRA,
-(CRa2)nC(O)CRA,

```
-(CRa_2)_nR^6,

-(CRa_2)_nC(O)OR^4, and

-(CRa_2)_nSi(R^4)_3;
```

### Ra is independently selected from

hydrogen, substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> alkyl, substituted or unsubstituted C<sub>2</sub>-C<sub>10</sub> alkenyl, substituted or unsubstituted C<sub>2</sub>-C<sub>10</sub> alkynyl, -OR<sup>4</sup>, -C(O)OR<sup>4</sup>, -NR<sup>4</sup>2, substituted or unsubstituted aryl, and substituted or unsubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl;

n is independently 0 to 6; t is 1 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. (Currently Amended) The compound according to Claim 1, wherein

#### R<sup>1</sup> is selected from

- 1) hydrogen,
- 2) halogen,
- 3) substituted or unsubstituted C1-C6 alkyl,
- 4) substituted or unsubstituted C2-C10 alkynyl,
- 5) substituted or unsubstituted aryl, and
- 6) substituted or unsubstituted C3-C10 cycloalkyl,

said alkyl, alkynyl, aryl, and cycloalkyl is optionally substituted with one or more of R7;

### R<sup>2</sup> is selected from

- 1) substituted or unsubstituted aralkyl,
- 2) substituted or unsubstituted C1-C6 alkyl,

- 3) substituted or unsubstituted aryl, and
- 4) substituted or unsubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl;

## R<sup>3</sup> is selected from

- 1) halogen,
- 2)  $-C(O)R^4$ , and
- 3) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl;

## R<sup>4</sup> is independently selected from

hydrogen, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl, substituted or unsubstituted aryl, and substituted or unsubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl;

or a pharmaceutically acceptable salt or stereoisomer thereof.

3. (Previously Presented) The compound according to Claim 2,

#### R1 is selected from

wherein

substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C10 alkynyl, and substituted or unsubstituted aryl;

said alkyl, alkynyl, and aryl is optionally substituted with one or more of R7;

## R<sup>2</sup> is selected from

- 1) substituted or unsubstituted aralkyl, and
- 2) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl;

### R<sup>3</sup> is selected from

- 1) halogen, and
- 2)  $-C(O)R^4$ ;

or a pharmaceutically acceptable salt or stereoisomer thereof.

### 4. (Previously Presented) A compound of Formula II

$$R^1$$
 $N$ 
 $H$ 
 $O$ 
 $O$ 
 $O$ 
 $O$ 
 $O$ 

wherein

#### R<sup>1</sup> is selected from

- 1) hydrogen,
- 2) halogen,
- 3) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl,
- 4) substituted or unsubstituted C2-C10 alkynyl,
- 5) substituted or unsubstituted aryl, and
- 6) substituted or unsubstituted C3-C10 cycloalkyl,

said alkyl, alkynyl, aryl, and cycloalkyl is optionally substituted with one or more of R<sup>7</sup>;

### R<sup>2</sup> is selected from

- 1) substituted or unsubstituted aralkyl, and
- 2) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl;

## R<sup>4</sup> is independently selected from

hydrogen, substituted or unsubstituted C1-C10 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C2-C10 alkenyl, and substituted or unsubstituted C2-C10 alkynyl;

## R6 is independently selected from

substituted or unsubstituted aryl, substituted or unsubstituted C3-C10 cycloalkyl, and halogen;

```
R<sup>7</sup> is independently selected from
               hydrogen,
                halogen,
                substituted or unsubstituted C1-C10 alkyl,
                substituted or unsubstituted C2-C10 alkenyl,
                substituted or unsubstituted C2-C10 alkynyl,
                substituted or unsubstituted C3-C10 cycloalkyl,
                substituted or unsubstituted aryl,
                -NO<sub>2</sub>,
                -NR4(CRa_2)_nC(O)R4,
                -(CRa_2)_nNR^42,
                -(CRa_2)_nNR^4(CRa_2)_nR^6
                -CN,
                -(CRa_2)_nC(O)R^4
                -(CRa_2)_nC(O)(CRa_2)_nOR^4,
                -(CRa_2)_nOR^4,
                -(CRa_2)_nR6
                -(CRa<sub>2</sub>)<sub>n</sub>C(O)OR<sup>4</sup>, and
               -(CRa_2)_nSi(R^4)_3;
Ra is independently selected from
                hydrogen,
                substituted or unsubstituted C1-C10 alkyl,
                substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> alkenyl,
                substituted or unsubstitute C1-C10 alkynyl,
                -OR4,
                -C(O)OR^4,
                -NR^{4}2,
                substituted or unsubstituted aryl, and
                substituted or unsubstituted C3-C10 cycloalkyl;
n is independently 0 to 6;
t is 1 to 4;
```

or a pharmaceutically acceptable salt or stereoisomer thereof.

### 5. (Previously Presented) A compound selected from:

benzyl 4-ethyl-2-formyl-1H-pyrrole-3-carboxylate; benzyl 4-ethyl-2-formyl-5-iodo-1H-pyrrole-3-carboxylate; methyl 4-ethyl-2-formyl-5-iodo-1H-pyrrole-3-carboxylate; methyl 4-ethyl-2,5-diiodo-1H-pyrrole-3-carboxylate; methyl 5-(4-fluorophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate; methyl 4-ethyl-2-formyl-5-thien-2-yl-1H-pyrrole-3-carboxylate; methyl 4-ethyl-2-formyl-5-[3-(trimethylsilyl)prop-1-ynyl]-1H-pyrrole-3-carboxylate; 4'-benzyl 1-tert-butyl 3'-ethyl-5'-formyl-1H,1'H-2,2'-bipyrrole-1,4'-dicarboxylate; benzyl 5-(3,5-dimethylisoxazol-4-yl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate; benzyl 5-(1-benzofuran-2-yl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate; benzyl 4-ethyl-2-formyl-5-(3-nitrophenyl)-1H-pyrrole-3-carboxylate; benzyl 4-ethyl-2-formyl-5-(5-methyl-2-furyl)-1H-pyrrole-3-carboxylate; benzyl 5-[3-(acetylamino)phenyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate; benzyl 4-ethyl-2-formyl-5-pyridin-4-yl-1H-pyrrole-3-carboxylate; benzyl 4-ethyl-2-formyl-5-phenyl-1H-pyrrole-3-carboxylate; benzyl 5-(3-cyanophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate; benzyl 4-ethyl-2-formyl-5-(3-methoxyphenyl)-1H-pyrrole-3-carboxylate; benzyl 4-ethyl-2-formyl-5-(5-formyl-2-furyl)-1H-pyrrole-3-carboxylate; methyl 4-ethyl-2-formyl-5-(phenylethynyl)-1H-pyrrole-3-carboxylate; methyl 5-{3-[benzyl(methyl)amino]prop-1-ynyl}-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate; benzyl 5-(2-cyanophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate; benzyl 5-(4-cyanophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

```
benzyl 4-ethyl-2-formyl-5-(4-nitrophenyl)-1H-pyrrole-3-carboxylate;
benzyl 4-ethyl-2-formyl-5-(2-methoxyphenyl)-1H-pyrrole-3-carboxylate;
benzyl 4-ethyl-2-formyl-5-(4-methoxyphenyl)-1H-pyrrole-3-carboxylate;
benzyl 4-ethyl-2-formyl-5-(2-methylphenyl)-1H-pyrrole-3-carboxylate;
benzyl 4-ethyl-2-formyl-5-(3-methylphenyl)-1H-pyrrole-3-carboxylate;
benzyl 5-(2-chlorophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
benzyl 5-(3-chlorophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-[1-(3-hydroxypropyl)vinyl]-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-(5-hydroxypent-1-ynyl)-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-[(1-hydroxycyclohexyl)ethynyl]-1H-pyrrole-3-carboxylate;
methyl 5-[3-(dimethylamino)prop-1-ynyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
methyl 5-(3,3-dimethylbut-1-ynyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-(pyridin-2-ylethynyl)-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-(6-methoxypyridin-2-yl)-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-(3-methoxyprop-1-ynyl)-1H-pyrrole-3-carboxylate;
methyl 5-[(2-bromophenyl)ethynyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
methyl 5-[3-(1H-1,2,3-benzotriazol-1-yl)prop-1-ynyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-5-(2-ethylbutyl)-2-formyl-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-(4-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-(6-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate;
methyl 5-(4-tert-butylphenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
methyl 5-(2,4-difluorophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-[3-(methoxycarbonyl)phenyl]-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-[4-(methoxycarbonyl)phenyl]-1H-pyrrole-3-carboxylate;
```

```
methyl 4-ethyl-2-formyl-5-[(1-hydroxycyclopentyl)ethynyl]-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-(3-hydroxy-3-methylbut-1-ynyl)-1H-pyrrole-3-carboxylate
methyl 4-ethyl-2-formyl-5-(1-hexylvinyl)-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-(1,3-thiazol-2-yl)-1H-pyrrole-3-carboxylate;
methyl 5-[1-(3-chloropropyl)vinyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
methyl 5-(5-chloropent-1-ynyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-(3-hydroxy-3-phenylbut-1-ynyl)-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-(3-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-isopentyl-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-(3-methylthien-2-yl)-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-isobutyl-1H-pyrrole-3-carboxylate;
methyl 5-cyclohexyl-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
methyl 5-butyl-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
methyl 5-cyclopentyl-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
methyl 5-(cyclohexylmethyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
methyl 5-sec-butyl-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-(3-methoxy-2-methyl-3-oxopropyl)-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-phenyl-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-pyridin-4-yl-1H-pyrrole-3-carboxylate;
methyl 4-ethyl-2-formyl-5-(4-nitrophenyl)-1H-pyrrole-3-carboxylate; and
methyl 4-ethyl-2-formyl-5-(2-methoxyphenyl)-1H-pyrrole-3-carboxylate;
or a pharmaceutically acceptable salt or stereoisomer thereof.
```

6. (Previously presented) The compound according Claim 5 that is selected

from methyl 4-ethyl-2-formyl-5-iodo-1H-pyrrole-3-carboxylate

benzyl 4-ethyl-2-formyl-5-phenyl-1H-pyrrole-3-carboxylate

methyl 4-ethyl-2-formyl-5-[(1-hydroxycyclohexyl)ethynyl]-1H-pyrrole-3-carboxylate

methyl 4-ethyl-2-formyl-5-(6-methoxypyridin-2-yl)-1H-pyrrole-3-carboxylate

methyl 5-[1-(3-chloropropyl)vinyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate

or a pharmaceutically acceptable salt or stereoisomer thereof.

7. (Previously Presented) A trifluoroacetic acid salt of a compound of Claim 5 which is selected from

methyl 4-ethyl-2-formyl-5-(6-methoxypyridin-2-yl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(4-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(6-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate; and

benzyl 4-ethyl-2-formyl-5-pyridin-4-yl-1H-pyrrole-3-carboxylate.

- 8. (Original) A pharmaceutical composition which is comprised of a compound in accordance with Claim 1 and a pharmaceutically acceptable carrier.
- 9. (Currently Amended) A method of modulating the catalytic activity of <u>IGF-1R protein kinases</u> in a mammal in need thereof comprising contacting the <u>IGF-1R protein kinase</u> with a compound of Claim 1.
  - 10. (Cancelled)
  - 11. (Cancelled)
  - 12. (Cancelled)
  - 13. (Cancelled)
  - 14. (Cancelled)

15.	(Cance	lled)
10.	( Carro	1100

- 16. (Original) A method of treating cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.
  - 17. (Cancelled)
  - 18. (Cancelled)
  - 19. (Cancelled)
  - 20. (Cancelled)
  - 21. (Cancelled)
  - 22. (Cancelled)
  - 23. (Cancelled)
  - 24. (Cancelled)
  - 25. (Cancelled)
  - 26. (Cancelled)
  - 27. (Cancelled)
  - 28. (Cancelled)
  - 29. (Cancelled)
  - 30. (Cancelled)